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ACh release by vagal nerve endings hyperpolarizes the membrane potential and induces a negative chronotropic and inotropic effect in the atria (6) . Hyperpolarization induced by an activation of M 2 mAChR-G i/o -K ACh ϩ channel signaling induces negative inotropic effect through an inhibition of L-type Ca 2ϩ channels. In addition to the role on the electromechanical functions, the cardiac cholinergic system is recently known to possess cardioprotective effects, including anti-ischemic (14) , anti-inflammatory (19) , and antihypertrophic (25) properties. Recently, the nonneuronal cholinergic system was identified in the heart. Cardiomyocytes express the ACh-synthesizing choline acetyltransferase and vesicular ACh transporter and release ACh (15, 24, 25) . Cardiomyocytes also express the ACh-degrading enzyme acetylcholinesterase (AChE) (15, 25) and M 2 mAChR (25) . Similarly, atrial cardiomyocytes express ACh-producing machinery, including choline acetyltransferase, vesicular ACh transporter, and high-affinity choline transporter-1, and release ACh (24) .
ANP is a member of the family of cardiac natriuretic peptides. ANP is primarily involved in the regulation of body fluid volume and blood pressure homeostasis. In addition, ANP possesses anti-ischemic, anti-inflammatory, and antihypertrophic properties (5, 8, 17, 30) . The receptors for ANP, guanylyl cyclase-coupled natriuretic peptide receptors, located on the plasma membrane of a variety of cells are involved in diverse cellular functions, including effects on ion channels and enzymes. Plasma levels of ANP are controlled in a narrow range by secretion from the heart and degradation by clearance receptors. The main secretion site involved in the physiological regulation of the plasma ANP levels is the atrial cardiomyocytes.
The roles of neuronal or nonneuronal ACh in the regulation of ANP secretion are not yet identified. Therefore, we hypothesize that endogenously released ACh regulates ANP secretion in an autocrine or paracrine manner in the cardiac atria. The present study is to verify the hypothesis in perfused beating rat atria. The present study shows that endogenously released ACh tonically stimulates ANP secretion via activation of the M 2 mAChR-G i/o -K ACh ϩ channel signaling.
MATERIALS AND METHODS
Animals. Male Sprague-Dawley rats (270 -300 g; Samtako, Osan, Korea) were used. The animal procedures were in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Utilization Committee for Medical Science of Wonkwang University.
Experimental protocols. To identify the role of endogenous ACh that was accumulated by exogenous intervention on ANP secretion, effects of an AChE inhibitor were tested. To evaluate the effects of physostigmine (eserine), an inhibitor of ACh degradation, on ANP secretion, experiments were performed in perfused beating rat atria. The atria were perfused for 30 min to stabilize atrial dynamics and ANP secretion, and to equilibrate the extracellular space with an extracellular space marker, [ 3 H]inulin (5 Ci/1.5 ml HEPES buffer). The control period (12 min) was followed by an introduction of vehicle for 36 min and then physostigmine (0, 0.03, 0.3, and 1.0 M) or vehicle for another 36 min. To test effects of exogenous ACh, the vehicle infusion was followed by ACh (30 nM) for 12 min (Fig. 1) . In another series of experiments, control period was followed by modulators (to be described later) for 36 min and then physostigmine (0.3 M) for 36 min in the continuous presence of the modulator. At the end of the experiment, effects of exogenous ACh in the presence of modulator were tested. Modulators include the following: high-affinity choline transporter inhibitor, hemicholinium-3 (HC-3, 1 and 10 M); mAChR inhibitors, nonselective mAChR and selective M 2 mAChR, atropine (3 M) and methoctramine (1 M), respectively; and K ACh ϩ channel inhibitor, tertiapin-Q (0.3 M). In another series of experiments, to identify the role of inhibitory G i/o proteins, effects of physostigmine were tested in the atria from rats treated with pertussis toxin (10 g/kg iv via tail vein, 3 days before experiment; see Refs. 9 and 32).
Perfused beating rat atrial preparation. Atria were prepared using a previously described method (18) , allowing electrical field stimula- tion and measurement of changes in atrial dynamics, intra-atrial pulse pressure, transmural extracellular fluid (ECF) translocation, and ANP secretion. Briefly, the heart was rapidly removed and placed in physiological saline, and the left atrium was dissected. An atrial cannula (8 cm long, 1.5 mm outer diameter) containing two small catheters within was inserted in the left atrium, and the cannula was secured by ligatures. The outer tip of the atrial cannula was open to allow outflow from the atrium. The cannulated atrium was transferred to an organ chamber containing HEPES buffer and [ 3 H]inulin (36.5°C; 5 Ci/1.5 ml HEPES buffer). The atrium was perfused with HEPES buffer solution (ϳ260 l/min). The composition of the buffer was (in mM): 118 NaCl, 4.7 KCl, 2.5 CaCl 2, 1.2 MgCl2, 25 NaHCO3, 10.0 glucose, and 10.0 HEPES containing 0.1% BSA (pH 7.4). Changes in intra-atrial pulse pressure were measured via a pressure transducer connected to an intra-atrial catheter and recorded on PowerLab (ML820; ADInstruments).
Measurement of the ECF translocation of the atrium and molecular concentration of ANP. The amount of ANP was also expressed in molar concentration in terms of ECF translocation (2) . To maintain an adequate equilibration for the measurement of the ECF translocation through the atrial wall, the atria were incubated for 20 min in the presence of an ECF marker, [ 3 H]inulin. The amount of ECF translocated through the atrial wall was calculated as follows (2), ECF translocated (l·min Ϫ1 ·g atrial wet wt Ϫ1 ) ϭ {[total radioactivity in perfusate (cpm/min)]/[radioactivity in pericardial reservoir (cpm/ l)]}/atrial wet wt (mg) ϫ 1,000. The molar concentration of ANP (M) ϭ (ANP secreted/ECF translocated)/molecular mass of ANP (2) . The molar concentration of ANP reflects the rate of atrial myocyte ANP release in the extracellular space.
Radioimmunoassay of ANP. The immunoreactive ANP in perfusate was measured by a selective radioimmunoassay as previously described (2). The radioimmunoassay was performed in Tris-acetate buffer (100 mM, pH 7.4) containing 0.2% neomycin, 1 mM EDTA, 50 BAEE U/ml soybean trypsin inhibitor, 0.02% sodium azide, 0.0004% phenylmethylsulfonyl fluoride, and 1% BSA. The secreted amount of ANP was expressed as nanograms ANP per minute per gram of atrial wet weight.
Reagents. Physostigmine, acetylcholine chloride, and atropine were purchased from Sigma-Aldrich (Yongin, Korea). HC-3 was purchased from Santa Cruz Biotechnology (Seoul, Korea). Tertiapin-Q and pertussis toxin were purchased from Tocris-Bioscience (Seoul, Korea). [ 3 H]inulin was purchased from PerkinElmer (Seoul, Korea). Physostigmine, ACh, atropine, and HC-3 were dissolved in distilled water. The concentration of HC-3 was in the range of the previous report (14) .
Statistical analyses. Significant differences were compared using repeated-measures ANOVA followed by Bonferroni's multiple-com- Values are means Ϯ SE; n, no. of experiments. ANP, atrial natriuretic peptide. The effects are expressed as percent differences (⌬% changes) before and 10 min after acetylcholine (ACh). Control ϩ ACh data are from Fig parison test. Student's t-test was also applied. Statistical significance was defined as P Ͻ 0.05. The results are shown as means Ϯ SE.
RESULTS

Effects of AChE inhibition on ANP secretion and modification by M 2 mAChR antagonist.
To identify the roles of endogenous ACh on ANP secretion, the effects of AChE inhibitor, which increases the availability of the ACh released, were tested in perfused beating rat atria. Basal levels of ANP secretion, ANP concentration, intra-atrial pulse pressure, but not ECF translocation decreased slightly but significantly ( Fig. 2A) . At the end of the experiment, as expected, exogenous ACh administration increased ANP secretion and ANP release concomitantly with a decrease in pulse pressure and ECF translocation ( Fig. 2A and Table 1 ). As shown in Fig. 2B, physostigmine (0.3 M) , an inhibitor of AChE, increased ANP secretion and the rate of ANP release concomitantly with a decrease in atrial pulse pressure and ECF translocation. The pattern of ANP secretion in response to physostigmine (Fig. 2Ba ) was similar to that of ANP release (Fig. 2Bb) . Physostigmine-induced changes in ANP release and pulse pressure were concentration dependent (Fig. 3) . Neostigmine (1 M), another inhibitor of AChE, similarly increased ANP release (76.23%, n ϭ 2) concomitantly with a decrease in pulse pressure (Ϫ52.06%, n ϭ 2). To further define the mechanisms by which physostigmine increases ANP secretion, effects of mAChR antagonists were tested. Atropine, a nonselective inhibitor of mAChR, significantly attenuated both the physostigmine-induced increase in ANP release and decrease in atrial pulse pressure (Fig. 4) . To further identify the subtype of the mAChRs involved, effects of a M 2 mAChR selective inhibitor, methoctramine, were tested. In the presence of methoctramine (1 M), the physostigmineinduced increase in ANP secretion and ANP release and decrease in pulse pressure were not observed (Figs. 2C and 4) . As expected, exogenous ACh-induced increase in ANP release and decrease in pulse pressure were attenuated in the presence of methoctramine (Table 1) . To further define the characteristics of the physostigmine-induced accentuation of ANP secretion via the M 2 mAChR signaling pathway, an involvement of pertussis toxin-sensitive inhibitory G proteins, G i/o , a downstream signaling pathway of the receptor, was tested. To identify the roles of G i/o proteins, the effects of physostigmine were tested in the atria from rats treated with pertussis toxin. As shown in Fig. 5 , physostigmine failed to increase ANP release in the atria from rats treated with pertussis toxin. Physostigmine-induced decrease in atrial dynamics was also not observed in the atria from rats treated with pertussis toxin. To further understand the mechanism involved in the physostigmine activation of ANP secretion, effects of an inhibitor of K ACh ϩ channel were tested. K ACh ϩ channel is a downstream target of G i/o proteins of the M 2 mAChR activation via G␤␥ signaling. In the presence of tertiapin-Q, an inhibitor of K ACh ϩ channel, physostigmine failed to increase ANP release and to decrease pulse pressure (Fig. 4) . Exogenous ACh-induced changes in ANP secretion and pulse pressure were attenuated by tertiapin-Q (Table 1 ). 
Effects of ACh synthesis inhibition on AChE inhibitor-induced accentuation of ANP secretion.
To further define the role of endogenously released ACh in the physostigmine-induced accentuation of ANP secretion, effects of an inhibition of ACh synthesis were tested. For this end, effects of HC-3, a specific inhibitor of high-affinity choline transporter, which is a ratelimiting factor for ACh synthesis (25) , were tested. In the presence of HC-3 (10 M), the physostigmine-induced increase in ANP secretion, ANP release, and decrease in atrial pulse pressure were significantly attenuated (Figs. 4 and 6B) . The effects of HC-3 on the physostigmine-induced changes in ANP secretion and pulse pressure were concentration-dependent (Fig. 4) . In the presence of HC-3, exogenous ACh (30 nM) increased ANP secretion and ANP release concomitantly with a decrease in pulse pressure similarly to the effects in the control group (Fig. 6A and Table 1 ).
Effects of inhibitors of ACh synthesis and mAChR on basal levels of ANP secretion.
It is noteworthy to observe effects of modulators of ACh on the basal levels of ANP release and pulse pressure. As shown in Figs. 2C and 7 , inhibitors of mAChR, atropine and methoctramine, and K ACh ϩ channel, tertiapin-Q, resulted in a decrease in ANP release and an increase in pulse pressure in the absence of physostigmine (Fig. 7) . Similarly, an inhibitor of ACh synthesis, HC-3, resulted in a decrease in ANP release and an increase in pulse pressure in a concentration-dependent manner (Figs. 6A and 7) .
DISCUSSION
The present study shows that inhibition of ACh degradation with an AChE inhibitor, physostigmine, accentuates ANP secretion concomitantly with a decrease in atrial dynamics in isolated beating rat atria. The effects were attenuated by inhibitors of the muscarinic cholinergic system. Inhibition of M 2 mAChR completely blocked the physostigmine-induced changes in secretory and contractile function. In the same line, inhibition of pertussis toxin-sensitive G i/o proteins and K ACh ϩ channels, which are M 2 mAChR downstream signaling pathways, completely blocked the responses to physostigmine. Furthermore, inhibition of ACh synthesis with HC-3 attenuated the physostigmine-induced changes in ANP secretion and atrial dynamics, which indicated an intact ACh synthesis is prerequisite for the changes. These findings suggest that physostigmine increases ANP secretion via activation of the M 2 muscarinic cholinergic system caused by an accumulation of the ACh released in the extracellular space of the atrium. Therefore, it is clear in the present study that endogenously released ACh increases ANP secretion via activation of M 2 mAChR-G i/o -K ACh ϩ channel signaling (Fig. 8) . Not only inhibition of the action but also suppression of the synthesis of ACh modulated the physostigmine stimulation of ANP secretion. It is also noteworthy that basal levels of ANP secretion are controlled by endogenously released ACh. Basal levels of ANP secretion were significantly decreased by blockade of ACh synthesis and M 2 mAChR signaling pathways, including M 2 mAChR and K ACh ϩ channels in the absence of physostigmine (Fig. 7) . These findings indicate that endogenously released ACh tonically stimulates ANP secretion via M 2 mAChR signaling in the cardiac atria. Therefore, in addition to the electromechanical roles, intrinsic ACh is coupled to activate ANP release from the atrial cardiomyocytes.
Recently, the nonneuronal cardiomyocyte cholinergic system has been identified (15, 24, 25) . The machinery for the synthesis, store, and release of ACh was identified in atrial and ventricular cardiomyocytes. Therefore, it is possible that endogenous ACh is involved in the regulation of ANP secretion in an autocrine or paracrine manner (Fig. 8) . However, the present study does not discriminate the source of ACh from either cardiac nerves, cardiomyocytes, or both of them.
Although effects of exogenous ACh on ANP secretion were reported in the cardiac atria, the roles of the intrinsic atrial cholinergic system on the regulation of ANP secretion are to be defined. Previously, it was shown that exogenous ACh enhances ANP secretion (11, 12, 18, 29, 32) . Exogenous ACh induced an increase in ANP secretion and decrease in atrial dynamics via activation of M 2 mAChR-G i/o -K ACh ϩ channel signaling (32) . It was also shown that pertussis toxin-sensitive G i/o proteins are involved in the stretch-induced ANP secretion (1) . The mechanism involved in the present findings of physostigmine on ANP secretion is in line with these reports.
HC-3 is known to suppress choline uptake through highaffinity choline transporter in the presynaptic nerve endings, which is the rate-limiting step of ACh synthesis (22, 23) . The present data showed that HC-3 inhibited the effects of physostigmine on the ANP secretion. This finding is consistent with the previous reports that inhibition of HC-3-sensitive choline transporter abolished myocardial ACh release (16) and effects of intrinsic ACh in the cardiomyocytes (25) as well as nerve terminals (10) . In addition to the effect on the ACh synthesis, HC-3 has also been reported to have antimuscarinic activity (20) . However, as shown in Table 1 , HC-3 has no effect on the ACh-induced changes in the secretory and contractile function.
The most important and prominent factor for the regulation of ANP secretion is the length changes of atrial cardiomyocytes (2, 3, 7) . Although the mechanisms involved in the mechanomolecular signaling of the cardiomyocyte ANP release are unknown, the roles of the modulating factors, including the autonomic nervous system and hormones, have been shown. Previously, it was shown that Ca 2ϩ entry via L-type Ca 2ϩ channel is negatively involved in the regulation of ANP secretion (4, 13, 26, 31) and tonically inhibits ANP release (31) . In the present study, it seems likely that an inhibition of Ca 2ϩ entry via L-type Ca 2ϩ channel is involved in the physostigmine-induced activation of ANP secretion. The steps suggested are as follows. 1) Physostigmine inhibition of the AChE activity results in an increase in ACh accumulation in the extracellular space of cardiomyocytes. 2) ACh released activates M 2 mAChR and leads to an activation of G i/o proteins and K ACh ϩ channels, which hyperpolarizes membrane potential of cardiomyocytes. 3) Hyperpolarization of cardiomyocytes inhibits Ca 2ϩ entry via L-type Ca 2ϩ channel, which is inhibitory against ANP release (Fig. 8). 4) The relief from the Ca 2ϩ inhibition of ANP release may accentuate the release (Fig. 8) . Therefore, intrinsic ACh release of the cardiac cholinergic system is coupled with ANP release (ACh-ANP signaling) in the regulation of body fluid volume and blood pressure homeostasis.
The present study shows for the first time that endogenous ACh is positively involved in the regulation of ANP secretion in the atria. Taken together with previous results (18, 32) , in cardiac atria, activation of the intrinsic muscarinic cholinergic system increases ANP secretion via an activation of the M 2 mAChR-G i/o -K ACh ϩ channel signaling, whereas the adrenergic system decreases the secretion via activation of the ␤ 1 -adrenergic receptor-L-type Ca 2ϩ channel signaling pathway. Neuronal and nonneuronal cardiac ACh is shown to be involved in the cardioprotection against ischemic, hypertrophic, and inflammatory stresses (14, 19, 25) . Similarly, the natriuretic peptide system is also known to possess antiinflammatory, anti-ischemic, and antihypertrophic activity (5, 8, 17, 30) . Therefore, it is possible that beneficial effects of ACh are related to the roles of the ANP system on cardioprotection through activation of the ACh-ANP signaling.
In summary, the present study identifies the physostigmineinduced accentuation of ANP secretion, suggesting that endogenous ACh released by exogenous intervention tonically stimulates ANP secretion from atrial cardiomyocytes via activation of M 2 mAChR-G i/o -K ACh ϩ channel signaling. Also, it is suggested that the ACh-ANP signaling is involved in the cardioprotection. 
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